IONS Valuation

Ionis Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

61.360

+0.35(0.574%)1D

Overview
Forecast
Valuation
Earnings

IONS Relative Valuation

IONS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IONS is overvalued; if below, it's undervalued.

Historical Valuation

Ionis Pharmaceuticals Inc (IONS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 14.59 is considered Undervalued compared with the five-year average of -29.25. The fair price of Ionis Pharmaceuticals Inc (IONS) is between 74.98 to 86.55 according to relative valuation methord. Compared to the current price of 61.01 USD , Ionis Pharmaceuticals Inc is Undervalued By 18.63%.

Relative Value

Fair Zone

74.98-86.55

Current Price：61.01

18.63%

Undervalued

-19.89

Trailing

Forward

-20.42

EV/EBITDA

Ionis Pharmaceuticals Inc. (IONS) has a current EV/EBITDA of -20.42. The 5-year average EV/EBITDA is -18.52. The thresholds are as follows: Strongly Undervalued below -46.16, Undervalued between -46.16 and -32.34, Fairly Valued between -4.70 and -32.34, Overvalued between -4.70 and 9.12, and Strongly Overvalued above 9.12. The current Forward EV/EBITDA of -20.42 falls within the Historic Trend Line -Fairly Valued range.

-14.49

EV/EBIT

Ionis Pharmaceuticals Inc. (IONS) has a current EV/EBIT of -14.49. The 5-year average EV/EBIT is -19.63. The thresholds are as follows: Strongly Undervalued below -82.65, Undervalued between -82.65 and -51.14, Fairly Valued between 11.87 and -51.14, Overvalued between 11.87 and 43.38, and Strongly Overvalued above 43.38. The current Forward EV/EBIT of -14.49 falls within the Historic Trend Line -Fairly Valued range.

14.60

Ionis Pharmaceuticals Inc. (IONS) has a current PS of 14.60. The 5-year average PS is 9.24. The thresholds are as follows: Strongly Undervalued below 5.78, Undervalued between 5.78 and 7.51, Fairly Valued between 10.97 and 7.51, Overvalued between 10.97 and 12.70, and Strongly Overvalued above 12.70. The current Forward PS of 14.60 falls within the Strongly Overvalued range.

-34.09

P/OCF

Ionis Pharmaceuticals Inc. (IONS) has a current P/OCF of -34.09. The 5-year average P/OCF is -21.77. The thresholds are as follows: Strongly Undervalued below -60.63, Undervalued between -60.63 and -41.20, Fairly Valued between -2.35 and -41.20, Overvalued between -2.35 and 17.08, and Strongly Overvalued above 17.08. The current Forward P/OCF of -34.09 falls within the Historic Trend Line -Fairly Valued range.

-21.40

P/FCF

Ionis Pharmaceuticals Inc. (IONS) has a current P/FCF of -21.40. The 5-year average P/FCF is -186.01. The thresholds are as follows: Strongly Undervalued below -1950.20, Undervalued between -1950.20 and -1068.10, Fairly Valued between 696.09 and -1068.10, Overvalued between 696.09 and 1578.18, and Strongly Overvalued above 1578.18. The current Forward P/FCF of -21.40 falls within the Historic Trend Line -Fairly Valued range.

Ionis Pharmaceuticals Inc (IONS) has a current Price-to-Book (P/B) ratio of 15.37. Compared to its 3-year average P/B ratio of 14.52 , the current P/B ratio is approximately 5.90% higher. Relative to its 5-year average P/B ratio of 11.88, the current P/B ratio is about 29.44% higher. Ionis Pharmaceuticals Inc (IONS) has a Forward Free Cash Flow (FCF) yield of approximately -2.98%. Compared to its 3-year average FCF yield of -5.99%, the current FCF yield is approximately -50.22% lower. Relative to its 5-year average FCF yield of -3.49% , the current FCF yield is about -14.51% lower.

15.46

P/B

Median3y

14.52

Median5y

11.88

-2.98

FCF Yield

Median3y

-5.99

Median5y

-3.49

Competitors Valuation Multiple

The average P/S ratio for IONS's competitors is , providing a benchmark for relative valuation. Ionis Pharmaceuticals Inc Corp (IONS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 100.69%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

IONS.O

Ionis Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Corcept Therapeutics Inc

Loss

18.70%

8.43B

Performance Decomposition

Market capitalization of IONS increased by 53.17% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -14.49 to -35.57.

The secondary factor is the Revenue Growth, contributed 100.69%to the performance.

Overall, the performance of IONS in the past 1 year is driven by P/E Change. Which is more unsustainable.

100.69%

225.25M → 452.05M

Revenue Growth

-192.90%

-29.42 → 27.33

Margin Expansion

145.38%

-14.49 → -35.57

P/E Change

53.17%